Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
MIGDAL HA'EMEQ, Israel, July 26, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) (“Enzymotec” or the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, announced today that the Company will release financial results for the second quarter ended June 30, 2017 on Wednesday, August 16, 2017, before the market opens. Following the release, Erez Israeli, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, August 16, 2017. Participants should dial +1 877-359-9508 (United States) or +1 224-357-2393 (International) with confirmation code #54908799 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/fsb2hqfy, and will be archived online within one hour of its completion.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
Company Contact Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Investor Relations Contact (U.S.) The Ruth Group Tram Bui / Alexander Lobo Phone: 646-536-7035 / 7037 [email protected] [email protected]
